Several ccRCC PDX models have been used to evaluate drug resistance,16, 17 and we previously used such a model to show that interleukin 13 receptor subunit alpha 2 mediates ccRCC sunitinib resistance.18 Here, IL13RA2 is linked to nonpapillary renal cell carcinoma.